IBRX — ImmunityBio, Inc. - Common Stock
Session close: $7.11. Regular-session share volume: 40,778,729. Change from previous close: -17.66%.
Key developments
ImmunityBio's third-quarter results missed expectations, with the adjusted loss per share and revenue both falling short of consensus and the adjusted net loss widening year over year. Net loss expanded sharply, which the reporting attributed to fair-value changes on a related-party convertible note and warrant and derivative liabilities tied to a higher stock price, plus higher interest, R&D and SG&A expenses. Revenue still grew strongly year over year.
Company news ImmunityBio Reports Wider Quarterly Loss · Company news ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates · Company news ImmunityBio: Q3 Earnings Snapshot
News sources
Company news ImmunityBio Reports Wider Quarterly Loss · Company news ImmunityBio Reports Q3 2026 Financial Results and Regulatory Milestones · Company news ImmunityBio Q3 Adj. EPS $(0.09) Misses $(0.08) Estimate, Sales $48.841M Miss $59.250M Estimate · Company news ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates · Company news ImmunityBio Reports Expanded ANKTIVA Approval And Global Market Expansion Across 35 Countries · Company news ImmunityBio: Q3 Earnings Snapshot · Company news ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million · Company news ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors · Company news ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ · Company news ImmunityBio Says ANKTIVA Plus BCG Meets Primary Endpoint In Phase 3 NMIBC Trial, Supports Planned FDA Filing · Company news ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial